LogicBio Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 3.2 million compared to USD 0.802 million a year ago. Net loss was USD 5.04 million compared to USD 10.5 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.33 a year ago. Diluted loss per share from continuing operations was USD 0.15 compared to USD 0.33 a year ago.
For the six months, revenue was USD 6.02 million compared to USD 1.26 million a year ago. Net loss was USD 11.71 million compared to USD 20.78 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 0.36 compared to USD 0.65 a year ago.